Upload
Featured Recent Articles Topics Login Upload

Search Results for 'response pfs'

response pfs published presentations and documents on DocSlides.

Median PFS: 2.6 months (95% CI, 1.7-3.5)
Median PFS: 2.6 months (95% CI, 1.7-3.5)
by ceila
Median PFS: 1.4 months (95% CI, 1.2-1.6) . Median ...
ESMO 2021 (Virtual) Congress Report
ESMO 2021 (Virtual) Congress Report
by SnuggleBug
Lung and gastrointestinal cancers. Slide numbers. ...
Update on Diagnosis and Treatments
Update on Diagnosis and Treatments
by joanne
of Multiple Myeloma. Kenneth C. Anderson, M.D.. J...
Summary 2011 Founded 2010
Summary 2011 Founded 2010
by eliza
in Houston. Vision: To be the leader in the develo...
Managing Advanced Renal Cell
Managing Advanced Renal Cell
by debby-jeon
Carcinoma: Balancing . Efficacy with Quality of L...
Btk inhibition in Mantle cell Lymphoma & CLL
Btk inhibition in Mantle cell Lymphoma & CLL
by test
Simon Rule. Professor of Clinical . Haematology. ...
Her-2 negative MBC
Her-2 negative MBC
by conchita-marotz
10/25/2016. Objectives. General principles. Endoc...
Immunotherapy for
Immunotherapy for
by sherrill-nordquist
High-Risk and Metastatic Melanoma. Timothy M. Kuz...
Impact of Imatinib interruption & duration of prior Hyd
Impact of Imatinib interruption & duration of prior Hyd
by pamella-moone
Raafat. R. Abdel-. Malek. , MD, FRCR. Ass. Prof ...
Overall Survival Benefit of
Overall Survival Benefit of
by tatyana-admore
Obinutuzumab. Over Rituximab when Combined with ...
Molecular Lessons Learnt from Clinical Trials in the Last Decade
Molecular Lessons Learnt from Clinical Trials in the Last Decade
by altigan
Andrew X. Zhu, MD, PhD. Harvard Medical School. Ma...
Updates on T-cell lymphoma
Updates on T-cell lymphoma
by grace3
Dr. Stefan K. Barta. University of Pennsylvania, U...
Impact of Imatinib interruption & duration of prior Hydroxyurea on treatment outcome in CML pat
Impact of Imatinib interruption & duration of prior Hydroxyurea on treatment outcome in CML pat
by hadly
Raafat. R. Abdel-. Malek. , MD, FRCR. Ass. Prof C...
GI CONNECT MEETING SUMMARY
GI CONNECT MEETING SUMMARY
by hanah
upper . gi. cancer HIGHLIGHTS . FROM ESMO 2022. D...
Meeting summary ASCO GU 2020,
Meeting summary ASCO GU 2020,
by patricia
San Francisco. , USA. Assoc. . Prof. . Shilpa Gupt...
meeting summary Autumn 2021 MEETINGS in Multiple Myeloma
meeting summary Autumn 2021 MEETINGS in Multiple Myeloma
by cadie
IMW | SOHO | SOHO Italy. Dr.. Claudio . Cerchione...
Paolo Ghia, 1 Andrzej Pluta,
Paolo Ghia, 1 Andrzej Pluta,
by HappyHippo
2. Malgorzata Wach,. 3. Daniel Lysak,. 4. Tomas...
The Impending D eath of Cancer:
The Impending D eath of Cancer:
by elina
A Herculean Task. Emerging Therapies 2016. Ruemu E...
Advances in Systemic Amyloidosis:
Advances in Systemic Amyloidosis:
by morton
A Spotlight on New Disease-Modifying . Therapies A...
by billiontins
2018;36(8):773-9.. Nivolumab Monotherapy (Cohort 1...
Targeting endocrine-resistance pathways in breast cancer
Targeting endocrine-resistance pathways in breast cancer
by alexa-scheidler
Targeting endocrine-resistance pathways in breas...
The Impending D eath of Cancer: A Herculean Task Emerging Therapies 2016
The Impending D eath of Cancer: A Herculean Task Emerging Therapies 2016
by phoebe-click
The Impending D eath of Cancer: A Herculean Task...
James Yang,
James Yang,
by pasty-toler
MD. The Evolving Treatment Landscape in NSCLC: Co...
Novel
Novel
by tatiana-dople
Agents . for . Indolent . L. ymphoma . and . Mant...
MEK Inhibitors and their potential role in relapsed NSCLC
MEK Inhibitors and their potential role in relapsed NSCLC
by debby-jeon
Ranee Mehra, MD. Fox Chase Cancer Center. Philade...
Update on transplant-ineligible patients:
Update on transplant-ineligible patients:
by trish-goza
Which . regimens are best?. Suzanne Lentzsch MD, ...
Acquired Resistance Patient Forum
Acquired Resistance Patient Forum
by test
September 6, 2014 | Boston. In ALK, ROS1 & EG...